Pentapeptide-decorated Silica Nanoparticles Loading Salmon Calcitonin for in Vivo Osteoporosis Treatment with Sustained Hypocalcemic Effect
P. Yu,Y. Chen,Y. Wang,Y. Liu,P. Zhang,Q. Guo,S. Li,H. Xiao,J. Xie,H. Tan,J. Li
DOI: https://doi.org/10.1016/j.mtchem.2019.08.008
IF: 7.613
2019-01-01
Materials Today Chemistry
Abstract:Patients with osteoporosis are at a constant risk of bone fracture, and traditional treatment involves the administration of anabolic or antiresorptive drugs. At present, antiosteoporosis drugs, including salmon calcitonin (sCT), face many challenges such as short half-life and limited therapeutic efficiency to suppress bone loss and increase bone mass. Therefore, strategies to prolong the action time of antiosteoporosis drugs in vivo and improve their efficacy are essential. In this study, pentapeptide-decorated silica nanoparticles were synthesized and loaded with sCT (SiO2-Pep@ sCT) to improve the therapeutic efficiency. Cytotoxicity and proliferation tests confirmed that SiO2-Pep@sCT had excellent biocompatibility. Biomarkers, including alkaline phosphatase activity, calcium flux, and calcified nodules, showed that SiO2-Pep@sCT promoted osteogenic differentiation in osteoblasts. Further, in vivo evaluations revealed that SiO2-Pep@sCT can efficiently prolong the half-life of sCT (from 30.5 to 69.3 min), leading to the maintenance of serum calcium in the normal physiological range in 48 h after single injection. For long-term treatment, micro-CT analysis showed that SiO2-Pep@sCT can enhance trabeculation and accelerate the process of bone repair during osteoporosis. Thus, the SiO2-Pep nanoparticle with uniform charge spatially distributed on the surface might be a potential drug/protein carrier for treating osteoporosis or other clinic diseases. (C) 2019 Elsevier Ltd. All rights reserved.